Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials
about
Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trialsDystrophin-deficient large animal models: translational research and exon skippingPotent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy.The golden retriever model of Duchenne muscular dystrophy.GRMD cardiac and skeletal muscle metabolism gene profiles are distinctOPN-a induces muscle inflammation by increasing recruitment and activation of pro-inflammatory macrophages.Whole genome sequencing reveals a 7 base-pair deletion in DMD exon 42 in a dog with muscular dystrophy.Histopathological Evaluation of Skeletal Muscle with Specific Reference to Mouse Models of Muscular Dystrophy.Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophyA scalable method for the production of high-titer and high-quality adeno-associated type 9 vectors using the HSV platform.Pathways Implicated in Tadalafil Amelioration of Duchenne Muscular Dystrophy.Are mice good models for human neuromuscular disease? Comparing muscle excursions in walking between mice and humans.Combined XIL-6R and urocortin-2 treatment restores MDX diaphragm muscle force.Glucose Metabolism as a Pre-clinical Biomarker for the Golden Retriever Model of Duchenne Muscular Dystrophy.The ubiquitin ligase tripartite-motif-protein 32 is induced in Duchenne muscular dystrophy.Expression profiling of disease progression in canine model of Duchenne muscular dystrophy.Sodium 4-phenylbutyrate reduces myofiber damage in a mouse model of Duchenne muscular dystrophy.Changes in Muscle Metabolism are Associated with Phenotypic Variability in Golden Retriever Muscular Dystrophy.At the Crossroads of Clinical and Preclinical Research for Muscular Dystrophy-Are We Closer to Effective Treatment for Patients?Supplementation with a selective amino acid formula ameliorates muscular dystrophy in mdx mice
P2860
Q26741409-BAAF4754-81AC-417E-9C3A-5C1011109842Q26781901-BC274088-F0C9-4AEA-B739-D7F776D50200Q30841381-BEF608B3-2484-4D7A-8BA8-4DF89A3C295CQ33709114-13C1BCE4-1DA9-41BF-B69E-32DD70301E23Q36340997-263CDB68-3347-45AC-B7BC-3484D8400827Q37394133-ED1E86F1-9E21-41A9-ADFF-FDEF5CE6DE30Q37727544-F7B5BD78-7991-48C3-9EFB-13485F6F7DC8Q38788613-C43A68D3-F953-4613-9A43-AC0F3B9FD6E4Q39410461-1810194E-E38B-48B1-BA5E-BC2343A97110Q39737661-9D8ACFA7-6D05-4A95-9C80-37DC32C03DD8Q40813682-91C8A590-8679-40A1-9770-6528FDCCBDC0Q45073133-4AFD90E5-E26A-4C06-8D56-0D302E0F7D85Q47949346-FD9FFC31-A04E-4CD7-9F34-A494D407D1DEQ51245941-6B6614EF-BB77-43C7-8321-7D245475C72BQ51705719-75AE05C1-7AAF-44C0-965F-EED3C2B8EB1CQ52648781-055F30CC-4060-45E7-A37E-1EE1C4C384ECQ53028251-AE82C0AC-8354-494E-BCDD-4A0FE8C198D9Q54988224-FC5A7FB4-0F2B-4CC7-99F6-33615B485CFCQ55361250-EDFDEB6B-A7B7-4F91-A672-FA0D746CCE30Q57050163-7659BC9B-6DD6-4989-BEFC-3316405E6D6B
P2860
Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pharmacologic management of Du ...... ication and preclinical trials
@ast
Pharmacologic management of Du ...... ication and preclinical trials
@en
Pharmacologic management of Du ...... ication and preclinical trials
@nl
type
label
Pharmacologic management of Du ...... ication and preclinical trials
@ast
Pharmacologic management of Du ...... ication and preclinical trials
@en
Pharmacologic management of Du ...... ication and preclinical trials
@nl
prefLabel
Pharmacologic management of Du ...... ication and preclinical trials
@ast
Pharmacologic management of Du ...... ication and preclinical trials
@en
Pharmacologic management of Du ...... ication and preclinical trials
@nl
P2093
P2860
P356
P1433
P1476
Pharmacologic management of Du ...... ication and preclinical trials
@en
P2093
Candice L Brinkmeyer-Langford
Christopher F Spurney
Eric P Hoffman
Joe N Kornegay
Peter P Nghiem
P2860
P304
P356
10.1093/ILAR/ILU011
P577
2014-01-01T00:00:00Z